Kristine M Erlandson1,2, Damani A Piggott3,4. 1. Department of Medicine, Division of Infectious Diseases, University of Colorado-Anschutz Medical Campus, 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO, 80045, USA. Kristine.erlandson@cuanschutz.edu. 2. Department of Epidemiology, Colorado School of Public Health, Anschutz Medical Campus, Aurora, CO, USA. Kristine.erlandson@cuanschutz.edu. 3. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD, USA.
Abstract
PURPOSE OF REVIEW: While the characteristics associated with frailty in people with HIV (PWH) have been well described, little is known regarding interventions to slow or reverse frailty. Here we review interventions to prevent or treat frailty in the general population and in people with HIV (PWH). RECENT FINDINGS: Frailty interventions have primarily relied on nonpharmacologic interventions (e.g., exercise and nutrition). Although few have addressed frailty, many of these therapies have shown benefit on components of frailty including gait speed, strength, and low activity among PWH. When nonpharmacologic interventions are insufficient, pharmacologic interventions may be necessary. Many interventions have been tested in preclinical models, but few have been tested or shown benefit among older adults with or without HIV. Ultimately, pharmacologic and nonpharmacologic interventions have the potential to improve vulnerability that underlies frailty in PWH, though clinical data is currently sparse.
PURPOSE OF REVIEW: While the characteristics associated with frailty in people with HIV (PWH) have been well described, little is known regarding interventions to slow or reverse frailty. Here we review interventions to prevent or treat frailty in the general population and in people with HIV (PWH). RECENT FINDINGS: Frailty interventions have primarily relied on nonpharmacologic interventions (e.g., exercise and nutrition). Although few have addressed frailty, many of these therapies have shown benefit on components of frailty including gait speed, strength, and low activity among PWH. When nonpharmacologic interventions are insufficient, pharmacologic interventions may be necessary. Many interventions have been tested in preclinical models, but few have been tested or shown benefit among older adults with or without HIV. Ultimately, pharmacologic and nonpharmacologic interventions have the potential to improve vulnerability that underlies frailty in PWH, though clinical data is currently sparse.
Entities:
Keywords:
Frailty interventions; HIV and aging; Mobility; Pillars of aging; Senolytics
Authors: Juliana Camacho-Pereira; Mariana G Tarragó; Claudia C S Chini; Veronica Nin; Carlos Escande; Gina M Warner; Amrutesh S Puranik; Renee A Schoon; Joel M Reid; Antonio Galina; Eduardo N Chini Journal: Cell Metab Date: 2016-06-14 Impact factor: 27.287
Authors: Alice E Kane; Sarah N Hilmer; Dawn Boyer; Kristan Gavin; Dawn Nines; Susan E Howlett; Rafael de Cabo; Sarah J Mitchell Journal: J Gerontol A Biol Sci Med Sci Date: 2015-02-22 Impact factor: 6.053
Authors: Damani A Piggott; Karen Bandeen-Roche; Shruti H Mehta; Todd T Brown; Huanle Yang; Jeremy D Walston; Sean X Leng; Gregory D Kirk Journal: AIDS Date: 2020-07-01 Impact factor: 4.177
Authors: David W Frederick; Emanuele Loro; Ling Liu; Antonio Davila; Karthikeyani Chellappa; Ian M Silverman; William J Quinn; Sager J Gosai; Elisia D Tichy; James G Davis; Foteini Mourkioti; Brian D Gregory; Ryan W Dellinger; Philip Redpath; Marie E Migaud; Eiko Nakamaru-Ogiso; Joshua D Rabinowitz; Tejvir S Khurana; Joseph A Baur Journal: Cell Metab Date: 2016-08-09 Impact factor: 27.287
Authors: Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal Journal: Nature Date: 2007-11-29 Impact factor: 49.962
Authors: Ian R McNicholl; Monica Gandhi; C Bradley Hare; Meredith Greene; Edgar Pierluissi Journal: Pharmacotherapy Date: 2017-11-30 Impact factor: 4.705
Authors: Ingo Beyer; Ivan Bautmans; Rose Njemini; Christian Demanet; Pierre Bergmann; Tony Mets Journal: BMC Musculoskelet Disord Date: 2011-12-30 Impact factor: 2.362
Authors: Robin K Minor; Joseph A Baur; Ana P Gomes; Theresa M Ward; Anna Csiszar; Evi M Mercken; Kotb Abdelmohsen; Yu-Kyong Shin; Carles Canto; Morten Scheibye-Knudsen; Melissa Krawczyk; Pablo M Irusta; Alejandro Martín-Montalvo; Basil P Hubbard; Yongqing Zhang; Elin Lehrmann; Alexa A White; Nathan L Price; William R Swindell; Kevin J Pearson; Kevin G Becker; Vilhelm A Bohr; Myriam Gorospe; Josephine M Egan; Mark I Talan; Johan Auwerx; Christoph H Westphal; James L Ellis; Zoltan Ungvari; George P Vlasuk; Peter J Elliott; David A Sinclair; Rafael de Cabo Journal: Sci Rep Date: 2011-08-18 Impact factor: 4.379
Authors: David R Lorenz; Shibani S Mukerji; Vikas Misra; Hajime Uno; Benjamin B Gelman; David J Moore; Elyse J Singer; Susan Morgello; Dana Gabuzda Journal: AIDS Date: 2021-12-01 Impact factor: 4.177